Jean-Marc Fellrath1, Thomas Scherer2, Daniel P Franzen3, Alban Lovis4, Christophe von Garnier5, Jérôme Plojoux6, Paola M Soccal6,7. 1. Department of Pulmonary Medicine, Pourtales Hospital, Neuchatel, Switzerland. 2. LungenZentrum Hirslanden, Zurich, Switzerland. 3. Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland. 4. Pneumology Division, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 5. Respiratory Medicine Department, Inselspital, University of Bern, Bern, Switzerland. 6. Division of Pulmonary Medicine, Geneva University Hospitals, Geneva, Switzerland. 7. Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Abstract
BACKGROUND: Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice. METHODS: The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment. RESULTS: patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (-0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (-4 points) 87%; 6MWD (+26 m) 60%. CONCLUSIONS: Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome.
BACKGROUND: Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice. METHODS: The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment. RESULTS: patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (-0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (-4 points) 87%; 6MWD (+26 m) 60%. CONCLUSIONS: Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome.
Authors: Jorine E Hartman; Nick H T Ten Hacken; Karin Klooster; H Marike Boezen; Mathieu H G de Greef; Dirk-Jan Slebos Journal: Eur Respir J Date: 2012-03-22 Impact factor: 16.671
Authors: Frank C Sciurba; Armin Ernst; Felix J F Herth; Charlie Strange; Gerard J Criner; Charles H Marquette; Kevin L Kovitz; Richard P Chiacchierini; Jonathan Goldin; Geoffrey McLennan Journal: N Engl J Med Date: 2010-09-23 Impact factor: 91.245
Authors: Frank C Sciurba; Gerard J Criner; Charlie Strange; Pallav L Shah; Gaetane Michaud; Timothy A Connolly; Gaëtan Deslée; William P Tillis; Antoine Delage; Charles-Hugo Marquette; Ganesh Krishna; Ravi Kalhan; J Scott Ferguson; Michael Jantz; Fabien Maldonado; Robert McKenna; Adnan Majid; Navdeep Rai; Steven Gay; Mark T Dransfield; Luis Angel; Roger Maxfield; Felix J F Herth; Momen M Wahidi; Atul Mehta; Dirk-Jan Slebos Journal: JAMA Date: 2016 May 24-31 Impact factor: 56.272
Authors: John E McDonough; Ren Yuan; Masaru Suzuki; Nazgol Seyednejad; W Mark Elliott; Pablo G Sanchez; Alexander C Wright; Warren B Gefter; Leslie Litzky; Harvey O Coxson; Peter D Paré; Don D Sin; Richard A Pierce; Jason C Woods; Annette M McWilliams; John R Mayo; Stephen C Lam; Joel D Cooper; James C Hogg Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Dirk Skowasch; Andreas Fertl; Björn Schwick; Harald Schäfer; Andreas Hellmann; Felix J F Herth Journal: Respiration Date: 2016-08-24 Impact factor: 3.580
Authors: Pallav L Shah; Zaid Zoumot; Suveer Singh; Stephen R Bicknell; Ewen T Ross; John Quiring; Nicholas S Hopkinson; Samuel V Kemp Journal: Lancet Respir Med Date: 2013-04-23 Impact factor: 30.700
Authors: Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood Journal: N Engl J Med Date: 2003-05-20 Impact factor: 91.245
Authors: Sebastian Mang; Niklas Huss; Hans-Joachim Schäfers; Holger Wehrfritz; Alexander Massmann; Christian Lensch; Frank Langer; Frederik Seiler; Robert Bals; Philipp M Lepper Journal: Interact Cardiovasc Thorac Surg Date: 2021-08-18
Authors: Sharyn A Roodenburg; Jorine E Hartman; Gaëtan Deslée; Felix J F Herth; Karin Klooster; Frank C Sciurba; Pallav L Shah; Arschang Valipour; Zaid Zoumot; Dirk-Jan Slebos Journal: Respiration Date: 2022-04-11 Impact factor: 3.966